) announced that it has made available the early onset
preeclampsia serum screening test, PreeclampsiaScreen T1, in the
U.S. The test would be useful in preventing preeclampsia, a
disease characterized by high blood pressure and high amounts of
protein in the urine of a pregnant woman, leading to delivery of
the fetus prior to 34 weeks' gestation.
ALERE INC (ALR): Free Stock Analysis Report
LEMAITRE VASCLR (LMAT): Free Stock Analysis
PERKINELMER INC (PKI): Free Stock Analysis
PLC SYSTEMS INC (PLCSF): Get Free Report
To read this article on Zacks.com click here.
Preeclampsia is a life threatening medical condition that affects
0.5% of all pregnancies, endangering the life of both the
pregnant mother and the baby. It is a major contributor to
maternal, fetal, and neonatal morbidity and mortality.
PreeclampsiaScreen test detects three biochemical markers in the
mother's blood: PAPP-A (pregnancy-associated plasma protein-A);
PlGF (placental growth factor) and AFP (alpha fetoprotein)
through a blood test in the first three months of pregnancy.
The test, evaluated collectively with personal demographic data,
provides an individual risk profile of developing early onset
preeclampsia in patients. Additionally, the sensitivity of the
test can be improved if physicians opt for two more biophysical
measurements for their patients, including arterial pressure
(MAP) and uterine artery Doppler pulsatility index (UtAD-PI).
Although some inexpensive medical treatments are available in the
form of low-dose aspirin for reducing the risk of preeclampsia,
they are effective only if begun early in the pregnancy. As a
result, the need for a first trimester screening is very
essential for the prevention of the disease. On early detection,
increased monitoring, modified activity, bed rest and medication
can help prevent the early onset preeclampsia.
For a long time, PerkinElmer is dedicated to offering products
and systems for prenatal clinical problems. Apart from the latest
offerings, PKI has offered non-invasive prenatal test based on
cell-free fetal DNA, and biochemical screening and SNP microarray
testing to detect birth defects and chromosome abnormalities.
In the second quarter of the year, this Zacks Rank #2 (Buy)
company posted adjusted earnings per share (EPS) of 51 cents,
beating the Zacks Consensus Estimate by 3 cents. However, the top
line lagged the year-ago earnings of 53 cents by nearly 4%.
Reported EPS fell 17.2% to 24 cents from 29 cents a year ago,
mainly due to a significant rise in restructuring and contract
Revenues in the quarter rose 4.1% to $543.3 million, exceeding
the Zacks Consensus Estimate of $534 million. The increase was
driven by improvements in PKI's both operating segments.
PerkinElmer expects organic revenues to increase in the
low-single digit range in the year compared with 2012. PKI also
expects reported earnings per share in the range of $1.40 to
$1.47 and adjusted earnings per share between $2.03 and $2.10
compared with the prior guidance of $2.00 to $2.10.
PerkinElmer, Inc. is a global technology company, which provides
products and systems to the telecom, medical, pharmaceutical,
chemical, semiconductor and photographic markets. PKI has
operations in over 100 countries, and is a component of the
S&P 500 Index.
Currently, other stocks that are also performing well in the
medical products industry include
PLC Systems Inc.
), both with a Zacks Rank #1 (Strong Buy), and
LeMaitre Vascular, Inc.
) with a Zacks Rank #2 (Buy).